Ruijia Chen

Ruijia Chen

Auto-generated profile, based on publicly available information

Ruijia Chen

Shanghai Key Laboratory of Chemical Biology, School of Pharmacy East China University of Science and Technology Shanghai China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2024 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
YLYun Lan
Yun Lan
QHQiaoying Han
Qiaoying Han
PLPingyong Liao
Pingyong Liao
RCRuijia Chen
Ruijia Chen
FFFei Fan
Fei Fan
WLWenbin Liu
Wenbin Liu

15 December 2021 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
ZQZhi Qiao
Zhi Qiao
WFWen Fu
Wen Fu
YZYongchao Zhang
Yongchao Zhang
RCRuijia Chen
Ruijia Chen
Zhi Ping XuZhi Ping Xu
Zhi Ping Xu
XSXusheng Shao
Xusheng Shao

7 January 2022 in Journal of Heterocyclic Chemistry
Verified
Journal Article
Closed access
PDF file
RCRui‐Jia Chen
Rui‐Jia Chen
CZCong Zhou
Cong Zhou
LDLe‐Feng Dong
Le‐Feng Dong
TFTing‐Ting Feng
Ting‐Ting Feng
GWGang‐Ao Wang
Gang‐Ao Wang
ZLZhong Li
Zhong Li

22 July 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
RCRuijia Chen
Ruijia Chen
YZYalan Zhang
Yalan Zhang
KLKongying Lin
Kongying Lin
DHDefu Huang
Defu Huang
MYMaoJin You
MaoJin You
NLNa Li
Na Li
Background: In the first-line treatment of biliary tract cancers (BTCs), XELOX (capecitabine plus oxaliplatin) showed comparable clinical efficacy and safety to gemcitabine and oxaliplatin (GEMOX), with fewer visits and better treatment management. Our study aims to investigate the cost-effectiveness of XELOX and GEMOX as the first-line therapy for BTCs from the perspective of the Chinese healthcare systems and to provide valuable suggestions for clinical decision-making.Methods: A Markov model was developed using the phase 3 randomized clinical trial (ClinicalTrials.gov number, NCT01470443) to evaluate the cost-effectiveness of XELOX and GEMOX. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were used as the primary outcomes of the model. Uncertainty was assessed using univariate and probabilistic sensitivity analysis.Results: The QALYs for the XELOX and GEMOX groups were 0.66 and 0.54, respectively. In China, the total cost of XELOX treatment is US $12,275.51, which is lower than that of the GEMOX regimen. In addition, XELOX is more effective than GEMOX, making it the preferred regimen. A sensitivity analysis determined that XELOX therapy has a stable economic advantage in China.Conclusion: Compared to GEMOX, XELOX is a more cost-effective treatment as a first-line treatment for advanced BTC from the perspective of the Chinese health service system.

2 April 2021 in Journal of Heterocyclic Chemistry
Verified
Journal Article
Closed access
PDF file
RCRui‐Jia Chen
Rui‐Jia Chen
JWJun‐Jie Wang
Jun‐Jie Wang
LHLi Han
Li Han
Yu-Cheng GuYu-Cheng Gu
Yu-Cheng Gu
ZXZhi‐Ping Xu
Zhi‐Ping Xu
ZLZhong Li
Zhong Li

15 March 2024 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
RCRui‐Jia Chen
Rui‐Jia Chen
ZZZi‐Hua Zhang
Zi‐Hua Zhang
SYShenglan Yang
Shenglan Yang
SYShu‐Chen Yu
Shu‐Chen Yu
JWJun‐Chang Wang
Jun‐Chang Wang
WLWenbin Liu
Wenbin Liu